neuropeptide-y and Causalgia

neuropeptide-y has been researched along with Causalgia* in 2 studies

Trials

1 trial(s) available for neuropeptide-y and Causalgia

ArticleYear
Plasma neuropeptide Y in the symptomatic limb of patients with causalgic pain.
    Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 1994, Volume: 4, Issue:3

    The aim of this experiment was to measure the concentration of neuropeptide Y (NPY), a vasoactive transmitter which co-exists with noradrenaline in sympathetic nerve terminals, in venous blood taken from the painful and contralateral limbs of 16 patients with features of reflex sympathetic dystrophy (RSD) or causalgia. In nine patients tapping the skin of the affected limb provoked pain (allodynia). In seven of the nine patients with allodynia the concentration of NPY was lower on the painful side; similar results were obtained in only two of seven patients without widespread allodynia. In addition, the concentration of NPY was generally lower in the painful limb if it was warmer than the contralateral limb. These findings suggest that a reduction in sympathetic activity might accompany allodynia and influence vasomotor disturbances in patients with causalgic pain.

    Topics: Adolescent; Adult; Arm; Causalgia; Female; Functional Laterality; Humans; Leg; Male; Middle Aged; Neuropeptide Y; Pain

1994

Other Studies

1 other study(ies) available for neuropeptide-y and Causalgia

ArticleYear
Nerve injury increases an excitatory action of neuropeptide Y and Y2-agonists on dorsal root ganglion neurons.
    Neuroscience, 1999, Volume: 89, Issue:1

    Damage to sensory nerves invokes the expression of neuropeptide Y in the cell bodies of sensory neurons in dorsal root ganglia. We therefore compared the action of this peptide on control dorsal root ganglia neurons with its action on neurons from animals in which the sciatic nerve had been cut. Neuropeptide Y (0.1-1.0 microM) increased the excitability of 24% of control neurons and its effect was stronger and more cells (56%) were affected after axotomy. Increased excitability was mediated via a Y2-receptor and resulted from attenuation of Ca2+-sensitive K+-conductance(s) secondary to suppression of N-type Ca2+ channel current. Y1-agonists potentiated L-type Ca2+ channel current in control neurons without altering excitability. This Y1-effect was attenuated whereas effects mediated via Y2-receptors were enhanced after axotomy. No evidence was found for involvement of Y4- or Y5-receptor subtypes in the actions of neuropeptide Y either on control or on axotomized dorsal root ganglion neurons. It is concluded that neuropeptide Y increases the excitability of sensory neurons by interacting with a Y2-receptor and thereby decreasing N-type Ca2+ channel current and Ca2+-sensitive K+-conductance(s). When peripheral nerves are damaged, dorsal root ganglion neurons start to express neuropeptide Y and its excitatory Y2-excitatory effects are enhanced. The peptide may therefore contribute to the generation of aberrant sensory activity and perhaps to the etiology of injury-induced neuropathic pain.

    Topics: Action Potentials; Adrenergic alpha-Agonists; Animals; Axotomy; Barium; Calcium; Calcium Channel Blockers; Calcium Channels; Causalgia; Ganglia, Spinal; GTP-Binding Proteins; Male; Neurons, Afferent; Neuropeptide Y; Nifedipine; Norepinephrine; omega-Conotoxin GVIA; Patch-Clamp Techniques; Peptide Fragments; Peptide YY; Peptides; Potassium; Potassium Channels; Rats; Rats, Sprague-Dawley; Receptors, Neuropeptide Y; Sciatic Nerve

1999